| Drug General Information |
| Drug ID |
D0H0FX
|
| Former ID |
DND000051
|
| Drug Name |
NCX-6560
|
| Synonyms |
NCX 6560
|
| Indication |
Cardiovascular disorder [ICD10:I00-I99]
|
Phase 1 |
[1]
|
|---|
| Company |
NicOx
|
| Structure |
|
Download
2D MOL
|
| Target and Pathway |
| Target(s) |
3-hydroxy-3-methylglutaryl-coenzyme A reductase |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
|
|
Superpathway of cholesterol biosynthesis
|
|
Mevalonate pathway
|
|
KEGG Pathway
|
Terpenoid backbone biosynthesis
|
|
Metabolic pathways
|
|
Biosynthesis of antibiotics
|
|
AMPK signaling pathway
|
|
Bile secretion
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
TSH Signaling Pathway
|
|
PANTHER Pathway
|
Cholesterol biosynthesis
|
|
PathWhiz Pathway
|
Steroid Biosynthesis
|
|
WikiPathways
|
Statin Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Cholesterol Biosynthesis
|
| References |
| REF 1 | Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. |
|---|
